Sharon, PA, United States of America

Infectech, Inc.


USPTO Granted Patents = 31

Forward Citations = 172

Loading Chart...
Loading Chart...

7 inventors (with patents filed for the assignee):

goldMedal Robert-A Ollar (19 out of 20 patents)

silverMedal Mitchell S Felder (18 out of 24 patents)

bronzeMedal Robert A Ollar (8 out of 8 patents)

4.  Robert- A Ollar (3 out of 3 patents)

5.  Thomas A Kelly (1 out of 1 patent)

6.  Robert -a Ollar (1 out of 1 patent)

7.  Sara J Giordano (1 out of 1 patent)


Core Competencies:
Apoptosis
Bioremediation
Antimicrobial Agents
Microbial Sensitivity
Mycobacterium
Paraffinophilic
Nonparaffinophilic
Testing Apparatus
Antibiotic Sensitivity
Microorganisms
Hazardous Substances
Presence Detection

31 patents:

Company Overview
Infectech, Inc. is a biotechnology company based in Sharon, Pennsylvania, specializing in the development of innovative solutions for infectious disease management. The organization focuses on advanced diagnostics and therapeutic technologies aimed at improving patient outcomes and enhancing public health. With a commitment to research and development, Infectech leverages cutting-edge science to address critical challenges in the healthcare sector, particularly in the realm of infectious diseases.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

31 Patents

#2 in Sharon, PA

#397 in Pennsylvania

#10,927 in US

#21,260 in the World

Sharon, PA (US)
Sharon, PA, United States of America
Forward Citations = 172

7 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Infectech, Inc.. Retrieved from https://idiyas.com/company/infectech

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…